Huang Peng, Wen Feng, Wang Xin
Division of Abdominal Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Front Pharmacol. 2024 Aug 13;15:1431542. doi: 10.3389/fphar.2024.1431542. eCollection 2024.
Metastatic colorectal cancer (mCRC) is characterized by significant phenotypic heterogeneity at the molecular level and presents a poor prognosis. Chemotherapy is commonly employed as the primary treatment option. Nevertheless, the advantages of chemotherapy are constrained, underscoring the critical necessity for novel treatment protocols aimed at enhancing patient outcomes. Human epidermal growth factor receptor 2 (HER2) has been recognized as a promising therapeutic target in mCRC. Pyrotinib, an innovative irreversible dual tyrosine kinase inhibitor targeting HER2, effectively inhibits cancer progression in various types of human cancers. Here, we present a case of a 39-year-old female with metastatic rectal cancer showing amplification of HER2. Despite resistance to multiple therapies, including trastuzumab and pertuzumab, the patient exhibited a remarkable therapeutic response to pyrotinib, tegafur combined with radiotherapy. This case provides evidence for the feasibility and potential efficacy of deploying pyrotinib in the salvage treatment of mCRC patients with HER2 amplification even though resistant to other anti-HER2 drugs.
转移性结直肠癌（mCRC）在分子水平上具有显著的表型异质性，预后较差。化疗通常作为主要的治疗选择。然而，化疗的优势受到限制，这凸显了开发旨在改善患者预后的新型治疗方案的迫切必要性。人表皮生长因子受体2（HER2）已被认为是mCRC中有前景的治疗靶点。吡咯替尼是一种创新的不可逆双靶点酪氨酸激酶抑制剂，可有效抑制多种人类癌症的肿瘤进展。在此，我们报告一例39岁转移性直肠癌女性患者，其HER2基因扩增。尽管对包括曲妥珠单抗和帕妥珠单抗在内的多种治疗耐药，但该患者对吡咯替尼联合替加氟及放疗表现出显著的治疗反应。该病例为吡咯替尼用于HER2扩增的mCRC患者的挽救治疗提供了可行性及潜在疗效的证据，即便这些患者对其他抗HER2药物耐药。
